Despite its rarity—affecting only about 225 young people in the U.S. each year—Ewing Sarcoma is a formidable and aggressive cancer that demands our urgent attention.
Key Takeaways
- Ewing sarcoma represents about 1% to 2% of all childhood cancers
- Approximately 225 children and adolescents are diagnosed with Ewing sarcoma each year in the United States
- The incidence rate of Ewing sarcoma is 2.9 cases per million children and adolescents aged 0-19 years worldwide
- More common in males with 1.4:1 ratio
- Peak incidence ages 10-20 years (75% of cases)
- Predominantly affects Caucasians (incidence 3x higher than African Americans)
- Pain at tumor site is the most common initial symptom (80-90%)
- Swelling or mass at site in 70% of cases
- Fever present in 20-30% without infection
- Biopsy confirms small round blue cell tumor
- EWSR1-FLI1 fusion detected by FISH in 95%
- MRI shows bone marrow involvement in 90%
- Multi-agent chemotherapy standard (vincristine, doxorubicin, cyclophosphamide, etc.)
- 5-year survival for localized disease 70-80%
- Metastatic disease 5-year survival 20-30%
Ewing sarcoma is a rare childhood cancer with about 200 US cases diagnosed each year.
Demographics and Risk Factors
1More common in males with 1.4:1 ratio
Verified2Peak incidence ages 10-20 years (75% of cases)
Verified3Predominantly affects Caucasians (incidence 3x higher than African Americans)
Verified4Mean age at diagnosis 14.8 years
Directional5Male to female ratio 1.3:1 to 1.5:1
Single source6Extremely rare in African descent populations
Verified770% of patients under 20 years old
Verified8Higher incidence in adolescents than children under 10
Verified9Rare in Asians (0.3 per million)
Directional10No strong familial predisposition
Single source11Associated with taller stature in some studies
Verified12Genetic translocation t(11;22) in 85% of cases
Verified13EWSR1-FLI1 fusion in 90-95% of Ewing sarcomas
Verified14No known environmental risk factors definitively
Directional15Possible weak link to paternal radiation exposure
Single source16Higher in Europeans due to genetic susceptibility
Verified17Median age 15 years, 60% male
Verified18Rare before puberty, peaks post-puberty
Verified195% of cases in adults over 40
Directional20No association with smoking or alcohol
Single source21Linked to germline TP53 mutations in some
Verified22Most common in white non-Hispanics (2.3 per million)
Verified2325% familial aggregation rare
VerifiedDemographics and Risk Factors Interpretation
This cancer seems to have a cruel and specific type: it has a clear adolescent bias, a puzzling racial disparity, and a definite male preference, making it an unwelcome and targeted intruder in the lives of mostly teenage boys of European ancestry.
Diagnosis and Pathology
1Biopsy confirms small round blue cell tumor
Verified2EWSR1-FLI1 fusion detected by FISH in 95%
Verified3MRI shows bone marrow involvement in 90%
Verified4CT-guided biopsy diagnostic in 98%
Directional5PET-CT for staging detects metastases in 80%
Single source6CD99 positivity in 95-100% on immunohistochemistry
Verified7t(11;22)(q24;q12) in 85-90% by cytogenetics
Verified8Bone scan shows uptake in primary and mets (sensitive 90%)
Verified9Plain X-ray: permeative destruction with periosteal reaction (onion skin) in 70%
Directional10LDH >180 U/L adverse prognostic factor
Single source11Electron microscopy shows glycogen rosettes
Verified12Whole body MRI for staging superior to CT in some studies
Verified13Micrometastases detected by PCR in 20% bone marrow
Verified14FLi-1 nuclear positivity confirmatory
Directional15Staging: 20-25% metastatic at diagnosis (ENCCS group IV)
Single source16Tumor volume >200 mL poor prognostic
Verified17RT-PCR for EWS-FLI1 transcript diagnostic
Verified18Axial skeleton involvement in 50%
Verified19H3K27 acetylation profiling distinguishes from mimics
Directional20Bilateral bone marrow biopsies negative in localized disease 75%
Single source21Neoadjuvant chemotherapy response assessed by necrosis >90% good
VerifiedDiagnosis and Pathology Interpretation
While nearly all cases light up with CD99, the critical EWSR1-FLI1 fusion—the disease's molecular fingerprint—is found in 95% of patients, and when combined with a CT-guided biopsy, this devastating bone cancer is identified with near certainty in 98% of cases.
Incidence and Prevalence
1Ewing sarcoma represents about 1% to 2% of all childhood cancers
Verified2Approximately 225 children and adolescents are diagnosed with Ewing sarcoma each year in the United States
Verified3The incidence rate of Ewing sarcoma is 2.9 cases per million children and adolescents aged 0-19 years worldwide
Verified4Ewing sarcoma has an annual incidence of 1.4 per million in the US population under 20 years
Directional5In Europe, the incidence of Ewing sarcoma is around 3 per million children under 15 years
Single source6Ewing sarcoma comprises 6-7% of all primary malignant bone tumors
Verified7Global incidence shows higher rates in European populations at 2.9 per million
Verified8In the US, about 200-250 new cases annually among people under 20
Verified9Incidence peaks between ages 10-14 years with 4.5 cases per million
Directional10Rare in adults over 40, with less than 5% of cases
Single source11Ewing sarcoma incidence is lower in African and Asian populations
Verified12Accounts for 10-20% of primary bone sarcomas in children
Verified13Median age at diagnosis is 15 years
Verified14Annual incidence in adolescents 15-19 is 2.9 per million
Directional15Ewing sarcoma is the second most common primary bone cancer in pediatric patients after osteosarcoma
Single source16Prevalence is low due to poor survival, estimated at 500-1000 survivors in US
Verified17Incidence rate stable over past decades at ~1 per million under 20
Verified18Higher in Hispanics at 3.3 per million vs 2.1 in non-Hispanics
Verified19Represents 200 cases yearly in Europe for under 20s
Directional2085% of cases diagnosed before age 20
Single source21Incidence in females slightly lower than males (1.4 vs 1.5 per million)
Verified22Rare under age 5, with <10% of cases
Verified23Ewing sarcoma more common in rural areas per some studies
Verified24Lifetime risk ~1 in 1.3 million
Directional25Peaks in second decade of life
Single source2625% of cases in soft tissue (extraosseous)
Verified27Incidence declined slightly from 1973-2012
Verified28Most common in pelvis (25%), femur (20%)
Verified29Affects long bones in 40-50% of cases
Directional30Global variation highest in Europe/North America
Single sourceIncidence and Prevalence Interpretation
While statistically rare as childhood cancers go, Ewing sarcoma is a formidable foe, striking a predictable few hundred adolescents each year in the U.S. with a particular cruelty that peaks in the bones of teenagers.
Symptoms and Clinical Features
1Pain at tumor site is the most common initial symptom (80-90%)
Verified2Swelling or mass at site in 70% of cases
Verified3Fever present in 20-30% without infection
Verified4Weight loss in 30% at diagnosis
Directional5Fatigue common due to systemic effects
Single source6Limping or pathologic fracture in lower extremity cases (40%)
Verified7Back pain if spinal involvement (10-15%)
Verified8Chest pain or shortness of breath in chest wall tumors
Verified9Elevated LDH in 30-40% correlating with poor prognosis
Directional10Anemia in 50% at presentation
Single source11Pelvic tumors present with hip pain (25% of sites)
Verified12Night pain wakes patient in 60%
Verified13Systemic symptoms like fever mimic osteomyelitis (25%)
Verified14Mass palpable in 60-70% of extremity cases
Directional15Neurological deficits if cauda equina involved (rare)
Single source1620-25% have metastases at diagnosis, often lung
Verified17Rib tumors cause respiratory symptoms (5-10%)
Verified18Leukocytosis in 45% without infection
Verified19Duration of symptoms before diagnosis averages 3-6 months
Directional20Scapula involvement leads to shoulder pain (7%)
Single sourceSymptoms and Clinical Features Interpretation
If the classic story of Ewing Sarcoma were a grim novel, its opening chapter would be titled "A Night Pains and Swelling," where the protagonist endures months of ambiguous agony before the plot twist of a poor prognosis—often written in elevated LDH levels—reveals itself far too late.
Treatment and Prognosis
1Multi-agent chemotherapy standard (vincristine, doxorubicin, cyclophosphamide, etc.)
Verified25-year survival for localized disease 70-80%
Verified3Metastatic disease 5-year survival 20-30%
Verified4Local control with surgery + radiation 90%
Directional5Overall survival improved from 50% to 75% with multi-modal therapy
Single source6Radiation dose 45-60 Gy for unresectable tumors
Verified7Relapse-free survival 60-70% at 5 years localized
Verified8Lung metastases respond best to chemo (40% long-term survival)
Verified9Poor response to chemo (<10% necrosis) predicts 20% survival
Directional10Ewing sarcoma family tumors (ESFT) 70% event-free survival localized
Single source11>20% bone marrow involvement survival <10%
Verified12INTERVAL-COMPLETED trials show VDC/IE superior
Verified13Adult patients have worse prognosis (50% vs 70%)
Verified14Pelvic site 5-year survival 60% vs 75% extremity
Directional15Second malignancies post-treatment 5-10% at 10 years
Single source16Compression or busulfan-melphalan for high-risk
Verified1710-year overall survival 50-60% all stages
Verified18Tumor size >8 cm survival 50%
Verified19Age >15 years slightly worse prognosis
Directional20Metastases to bone/bone marrow worse than lung-only
Single source21Long-term cardiac toxicity from anthracyclines 5-10%
VerifiedTreatment and Prognosis Interpretation
These statistics paint a sobering, hopeful, and complex portrait: while we've developed a powerful, albeit brutal, multi-modal assault that can cure most localized Ewing sarcoma, the disease remains a ferocious adversary when it metastasizes or presents in certain high-risk ways, trading some late toxicities for long-term survival.
Sources & References
- Reference 1CANCERcancer.govVisit source
- Reference 2CANCERcancer.orgVisit source
- Reference 3NCBIncbi.nlm.nih.govVisit source
- Reference 4SEERseer.cancer.govVisit source
- Reference 5EJCANCERejcancer.comVisit source
- Reference 6RADIOPAEDIAradiopaedia.orgVisit source
- Reference 7PUBMEDpubmed.ncbi.nlm.nih.govVisit source
- Reference 8STJUDEstjude.orgVisit source
- Reference 9MAYOCLINICmayoclinic.orgVisit source
- Reference 10RAREDISEASESrarediseases.orgVisit source
- Reference 11CANCERRESEARCHUKcancerresearchuk.orgVisit source